Company intelligence / Profile preview
Amarin Corporation plc
- Ownership
- Public · AMRN
- Employees
- ~275
- Development stage
- Commercial
Overview
Amarin’s lead product Vascepa® (icosapent ethyl) is FDA-approved for reducing triglyceride levels in adults with severe hypertriglyceridemia and for cardiovascular risk reduction as an adjunct to statin therapy. Vascepa has demonstrated significant clinical benefit in reducing major adverse cardiovascular events in at-risk populations. The company continues to pursue additional regulatory approvals internationally
- Therapeutic areas
- CardiovascularNeurologyMetabolic Disorders
- Modalities
- small molecules (notably prescription-grade omega-3 fatty acid/icosapent ethyl)
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Partnerships
Financials
- Market cap
- $239.4M
- Total revenue
- $213.6M
- Enterprise value
- $-76.4M
Beyond the preview
Go deeper on Amarin Corporation plc.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Amarin Corporation plc.